Ivacaftor Aliud (Ivacaftor)

Ivacaftor is a CFTR potentiator used in the management of cystic fibrosis, targeting the underlying protein defect.

• Cystic fibrosis with G551D gating mutation: improves lung function and reduces frequency of pulmonary exacerbations.
• Cystic fibrosis with other responsive gating mutations (e.g., R117H): enhances chloride transport, leading to better respiratory outcomes.
• Cystic fibrosis with residual function mutations (when clinically appropriate): increases CFTR activity, supporting nutritional status and sweat chloride reduction.
• Cystic fibrosis patients eligible for monotherapy: provides an oral treatment option that addresses the basic defect in CFTR gating.

• Ivacaftor binds to the cystic fibrosis transmembrane conductance regulator (CFTR) protein at the cell surface and stabilizes its open conformation. By increasing the probability that the chloride channel remains open, the drug enhances chloride ion transport across epithelial membranes, improving hydration of airway surface liquid and restoring more normal mucus clearance in patients with gating mutations. The increased ion flow also contributes to better pancreatic and intestinal secretions, supporting overall organ function.

Ivacaftor may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Diarrhea: watery stools, may be self‑limiting.
• Nausea: occasional, usually resolves without intervention.
• Upper respiratory tract infection: symptoms of cold or mild sinusitis.
• Abdominal pain: cramp‑like discomfort in the stomach area.
• Fatigue: feeling of tiredness or reduced energy.
• Vomiting: occasional episodes, generally mild.

Serious or Rare Side Effects

• Elevated liver enzymes (ALT/AST): may indicate hepatic stress, requires monitoring.
• Cataracts: lens opacity developing over prolonged use, ophthalmologic evaluation advised.
• Severe rash or hypersensitivity reactions: includes Stevens‑Johnson syndrome, requires immediate medical attention.

When prescribing ivacaftor, clinicians should consider several precautionary measures to ensure safe use.

• Liver function monitoring: assess baseline ALT/AST and repeat periodically during therapy.
• Drug interaction awareness: avoid concomitant use with strong CYP3A inducers or adjust dose if necessary.
• Pregnancy and lactation: weigh potential benefits against unknown risks; discuss with patient.
• Renal impairment: use with caution in patients with severe kidney dysfunction, monitor renal parameters.
• Store at room temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Ivacaftor is metabolized primarily by CYP3A enzymes, leading to clinically relevant drug interactions.

Major Interactions (Avoid)

• Strong CYP3A inducers (e.g., rifampin, carbamazepine): markedly reduce ivacaftor exposure, compromising efficacy.
• Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole): significantly increase ivacaftor levels, raising risk of toxicity.
• Certain statins (e.g., simvastatin, lovastatin): increased statin exposure may cause myopathy.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: ivacaftor may lower hormone levels, reducing contraceptive effectiveness.
• Antacids containing aluminum or magnesium: may affect ivacaftor absorption; separate administration by at least 2 hours.
• Warfarin: monitor INR more frequently as ivacaftor may alter anticoagulant effect.